Core Viewpoint - Biohaven's main asset, Troriluzole, is under FDA review and has the potential for approval, which is a key driver for the company's stock performance [1] Group 1: Investment and Financial Support - Oberland Capital Management plans to inject up to $600 million into Biohaven, structured through milestone payments and royalties based on Troriluzole's future net sales [1] - Citigroup has assigned a "Buy" rating to Biohaven with a target price of $28 per share [1] Group 2: Regulatory Developments - The FDA recently canceled a planned advisory committee meeting for Troriluzole's marketing application for treating Spinocerebellar Ataxia (SCA), with the PDUFA target action date set for the fourth quarter [1] - The likelihood of Troriluzole receiving FDA approval is assessed to be over 50% based on clinical data, regulatory precedents, and the investment decision by Oberland Capital [1] Group 3: Stock Performance and Valuation - Biohaven's stock has declined nearly two-thirds over the past 12 months, with current valuations reflecting the risks associated with the PDUFA approval [2] - If Troriluzole is approved, significant upside potential for Biohaven's stock price is anticipated [2] - On Wednesday, Biohaven's stock rose by 8.97% to $14.7, with an after-hours increase of 4.42% to $15.35 [2]

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), of the important September 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Biohaven securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that affected investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for treating bipolar disorder [2]. - It is alleged that the misleading statements would likely have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these misstatements would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Points - The Law Offices of Frank R. Cruz is reminding investors about the September 12, 2025 deadline to participate as a lead plaintiff in a securities fraud class action lawsuit against Biohaven Ltd. [1] - The lawsuit is on behalf of investors who acquired Biohaven securities between March 24, 2023, and May 14, 2025, which is referred to as the "Class Period" [1]

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making materially false and misleading statements regarding its business and operations during the class period from March 24, 2023, to May 14, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Biohaven securities during the specified class period [2]. - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Biohaven overstated the regulatory prospects of its treatment, troriluzole, for SCA, and the sufficiency of data submitted for its regulatory approval [4]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were similarly overstated [4]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities between March 24, 2023, and May 14, 2025, of the September 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making false and misleading statements regarding its drug candidates, which may have negatively impacted investors [4] - Investors who wish to join the class action can do so without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lawsuit claims that the defendants overstated the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, leading to significant damages for investors when the truth was revealed [4] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [3]

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly making materially false and misleading statements regarding its business and operations during the class period from March 24, 2023, to May 14, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Biohaven securities during the specified class period [2]. - Investors have until September 12, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Biohaven overstated the regulatory prospects of its drug troriluzole as a treatment for SCA and the sufficiency of data submitted for regulatory approval [4]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were similarly overstated [4]. - The revelations regarding these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

NEW YORK--(BUSINESS WIRE)---- $BHVN #BHVN--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biohaven Ltd. ("Biohaven†or the "Company†) (NYSE: BHVN). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On May 14, 2025, Biohaven issued a press release "announc[in. ...

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that affected investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the sufficiency of data submitted for its regulatory approval [2]. - It is also alleged that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were overstated [2]. - The lawsuit suggests that the revelation of these issues would likely have a significant negative impact on Biohaven's business and financial condition, rendering the defendants' public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].